enVVeno Medical Corporation Stock

Equities

NVNO

US29415J1060

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:05 2024-04-23 pm EDT 5-day change 1st Jan Change
5.53 USD +12.63% Intraday chart for enVVeno Medical Corporation +16.18% +7.59%
Sales 2024 * - Sales 2025 * 24.32M Capitalization 65.38M
Net income 2024 * -26M Net income 2025 * -15M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.69 x
P/E ratio 2024 *
-3.51 x
P/E ratio 2025 *
-7.33 x
Employees 31
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.93%
More Fundamentals * Assessed data
Dynamic Chart
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 CI
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer CI
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
EnVVeno Achieves Full Enrollment for VenoValve Trial; to Conduct Preclinical Trial of Another Venous Valve Product MT
EnVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial CI
EnVVeno Medical Corporation announced that it expects to receive $27.997135 million in funding CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell 3000E Growth Index CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell Microcap Growth Index CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day+12.63%
1 week+16.18%
Current month+1.65%
1 month+0.73%
3 months+31.98%
6 months+1.10%
Current year+7.59%
More quotes
1 week
4.57
Extreme 4.57
5.56
1 month
4.57
Extreme 4.57
5.80
Current year
3.80
Extreme 3.8
6.97
1 year
2.51
Extreme 2.51
6.97
3 years
2.51
Extreme 2.51
11.38
5 years
2.51
Extreme 2.51
62.00
10 years
2.51
Extreme 2.51
141.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 18-03-31
Director of Finance/CFO 63 20-04-05
Chief Tech/Sci/R&D Officer - 20-12-29
Members of the board TitleAgeSince
Chief Executive Officer 61 18-03-31
Director/Board Member 63 19-09-15
Chief Tech/Sci/R&D Officer 75 16-04-30
More insiders
Date Price Change Volume
24-04-22 4.91 +6.28% 71,626
24-04-19 4.62 -3.35% 70,706
24-04-18 4.78 -0.42% 35,906
24-04-17 4.8 +0.84% 70,454
24-04-16 4.76 -3.25% 63,554

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.91 USD
Average target price
20.4 USD
Spread / Average Target
+315.48%
Consensus